Emerging Nanotechnologies in Immunology: The Design Applications and: Toxicology of Nanopharmaceuticals and Nanovaccines 1ed:. Cet article n’est pas disponible.Emerging Nanotechnologies in Immunology: The Design Applications and: Toxicology of Nanopharmaceuticals and Nanovaccines 1ed:

Emerging Nanotechnologies in Immunology aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanophamaceuticals currently in the pipeline of S&T development for skin, ocular, and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure. The scientific development of manufactured nanomaterials for drug delivery is increasing rapidly. One of the most prominent applications is topical drug delivery, where cutaneous, ocular, and nasal exposure becomes even more relevant. These targets are the first barrier that nanoparticles encounter when in contact with the human body. The contributors addresses a representative set of the broad spectrum of nanopharmaceuticals currently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue engineered skin substitutes. Regulation and risk is also covered, since the safety of these nanophamaceuticals still represents a barrier to their wide innovative use.

Ranjita Shegokar holds a Ph.D. degree in Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics at the Free University of Berlin, Germany. Currently, she serves as Chief Scientific Officer (CSO) at Capnopharm GmbH, Germany. She has authored several research articles, book chapters, and presented her research in many national/international conferences. She has filed multiple patent applications in the area of drug delivery and targeting. Besides that, she has edited many trending books in the area of pharmaceutical nanotechnology and drug delivery aspects. For her research, she has received many prestigious national and international awards among them include recently received prestigious German Innovation Award 2022. Her areas of interest include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting and the role of excipients in delivery systems. (www.ranjitas.com)

Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a master’s in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry.